Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington’s disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.本案提供一特定化合物、或其醫藥學上可接受之鹽或前藥。本案還提供一醫藥組成物，其包含至少一種本文所述化合物、或其醫藥學上可接受之鹽或前藥，和一種或多種醫藥學上可接受之媒介物。本案係描述治療患有對抑制KMO活性有反應的疾病和病症的病患的方法，所述方法包括向所述病患投予有效減少所述疾病或病症的病徵或症狀的一定量的至少一種本文所述化合物、或其醫藥學上可接受之鹽或前藥。這些疾病包括神經變性病症例如亨廷頓氏症。本案還描述了治療方法，其包括投予作為單一活性劑的至少一種本文所述化合物或其醫藥學上可接受之鹽或前藥，或投予至少一種本文所述化合物或其醫藥學上可接受之鹽或前藥與一種或多種其他治療劑的組合。本申請還提供篩選能够抑制KMO活性的化合物的方法。
